Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials

Recurrent respiratory tract infections (RRTIs) remain a great challenge to pediatricians, because they can increase the risk of various complications and there is no confirmed effective treatment. In the present study, we aimed to assess the effectiveness and safety of pidotimod (PDT), an immunostim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2019-02, Vol.67, p.35-45
Hauptverfasser:	Niu, Hui, Wang, Rui, Jia, Yu-ting, Cai, Yun
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants Antibiotics Antiinfectives and antibacterials Antiviral agents CD3 antigen CD4 antigen Child Children Clinical trials Complications Cough Fever Immunoglobulin A Immunoglobulin G Immunoglobulin M Immunologic Immunostimulants Infections Lymphocytes T Meta-analysis Patients Pediatrics Pidotimod Quality assessment Randomization Recurrent respiratory tract infections Respiratory tract Respiratory tract diseases Respiratory tract infection Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recurrent respiratory tract infections (RRTIs) remain a great challenge to pediatricians, because they can increase the risk of various complications and there is no confirmed effective treatment. In the present study, we aimed to assess the effectiveness and safety of pidotimod (PDT), an immunostimulant, in treatment of RRTIs in children aged 14 years and under. PubMed, EMBASE, Web of Science, Cochrane Library, ClinicalTrials.gov, CBM and CNKI were searched from their inception up to February 2018. All randomized controlled trials (RCTs) using PDT with various treatment durations and enrolling participants
ISSN:	1567-5769 1878-1705
DOI:	10.1016/j.intimp.2018.11.043